Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Michael J. Mauro, MD, Vivian G. Oehler, MD, James E. Thompson, MD, James K. McCloskey, MD, Michael C. Heinrich, MD, Shaker R. Dakhil, MD, Irene DeGutis, PharmD, David Tabano, PhD, Wasiulla Khan, PhD, Javid J. Moslehi, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137613

Published: 2020

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-139705

Published: 2020

Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133855

Published: 2020

Journal Articles

Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

Gee Youn (Geeny) Kim, PharmD, Jamie L. Koprivnikar, MD, Rebecca Testi, MSN, RN, APN-C, OCN, Tara McCabe, FNP-C, MSN, RN, BSN, Grace Perry, MSN, RN, APN-C, OCN, Danielle Marcotulli, MSN, RN, FNP-BC, AOCNP, Elizabeth Jones, BSN, RN, OCN, Xue Geng, MS, Ming Tan, James K. McCloskey, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-142891

Published: 2020

Journal Articles

Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis

Maher Albitar, Michele L. Donato, MD, David S. Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, James K. McCloskey, MD, Jamie L. Koprivnikar, MD, Andrew Ip, MDMSc, Andre H. Goy, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140049

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar, MD, James K McCloskey, MD, Rena Feinman, PhD, Robert Korngold, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD

Blood (2019) 134 (Supplement_1): 5618.

https://doi.org/10.1182/blood-2019-132025

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

One Size May Not Fit All for TKI Dosing in Chronic Phase CML—Deep Molecular Responses Despite Dose Reduction

James K McCloskey, MD, Genique Stanislaus, ANP, Yen-Hong Kuo, PhD, Jamie Koprivnikar, MD

Blood (2018) 132 (Supplement 1): 5448.

https://doi.org/10.1182/blood-2018-99-119971

Published: 2018

Journal Articles

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Adam Zrinski Albitar, BS, Neil Shah, MD, James K McCloskey, MD, Jamie L. Koprivnikar, MD, Jianhua Zhao, PhD, Chirag Desai, MS, MBA, Sucha Sudarsanam, MS, Maher Albitar, MD, Catherine E. Lai, MD

Blood (2018) 132 (Supplement 1): 1393.

https://doi.org/10.1182/blood-2018-99-117365

Published: 2018

Journal Articles

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Blood (2018) 132 (Supplement 1): 560.

https://doi.org/10.1182/blood-2018-99-110449

Published: 2018

Journal Articles

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

James K McCloskey, MD, Genique Stanislaus, ANP, Jamie L. Koprivnikar, MD, Tracy Andrews, PhD, Jones Elizabeth, Danielle Marcotulli, APN, Grace Perry, APN, Stuart L. Goldberg, MD, Stefan Faderl

Blood (2017) 130 (Supplement 1): 5050.

https://doi.org/10.1182/blood.V130.Suppl_1.5050.5050

Published: 2017

Journal Articles

TP53 Mutations Determine Outcome of Patients (pts) with High-Risk Myelodysplastic Syndrome (HRMDS) and Acute Myelogenous Leukemia (AML) Regardless of Karyotype and ELN Risk Stratification

James K. McCloskey, MD, Marshall McKenna, BA, Jamie L. Koprivnikar, MD, Samantha Depadova, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2016) 128 (22): 5242.

https://doi.org/10.1182/blood.V128.22.5242.5242

Published: 2016

Journal Articles

Outcome of Acute Myeloid Leukemia (AML) Induction Therapy Based on D14 Marrow Biopsy According to European Leukemia Net (ELN) Risk Classification

David Ray, PharmD, MBA, Jamie L. Koprivnikar, MD, James K. McCloskey, MD, Genique Stanislaus, ANP, Christina Howlett, PharmD, BCOP, Amy Davidow, PhD, Samantha Depadova, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2016) 128 (22): 5174.

https://doi.org/10.1182/blood.V128.22.5174.5174

Published: 2016

Journal Articles

Evaluation of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in the Oncology Population

Jessica Hedvat, PharmD, Christina Howlett, PharmD, BCOP, James K. McCloskey, MD, Ruchi Jain, PharmD, BCPS

Blood (2016) 128 (22): 5026.

https://doi.org/10.1182/blood.V128.22.5026.5026

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Blood (2016) 128 (22): 4245.

https://doi.org/10.1182/blood.V128.22.4245.4245

Published: 2016

Journal Articles

Features and Outcome of Patients (Pts) with New Diagnosis of Acute Myeloid Leukemia (AML) with Monocytic Differentiation (AML-Mo) Following Standard Induction Therapy. Do We Need a Different Strategy?

James K. McCloskey, MD, Samantha Depadova, Jamie L. Koprivnikar, MD, Tracy Andrews, MA, Marshall McKenna, BA, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2016) 128 (22): 4017.

https://doi.org/10.1182/blood.V128.22.4017.4017

Published: 2016

Journal Articles

A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR

James K. McCloskey, MD, Jamie L. Koprivnikar, MD, Stuart L. Goldberg, MD, Themba L Nyirenda, PhD, Genique Stanislaus, ANP, Christina Howlett, PharmD, BCOP, Stefan Faderl, MD

Blood (2015) 126 (23): 5168.

https://doi.org/10.1182/blood.V126.23.5168.5168

Published: 2015

Journal Articles

A Single Institution Retrospective Review of Characteristics and Outcomes of Patients Requiring Chronic Dose Reduction of TKIs Given As Front-Line Therapy for Chronic Phase CML

Jamie L. Koprivnikar, MD, James K. McCloskey, MD, Yucai Wang, MD PhD, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2015) 126 (23): 5171.

https://doi.org/10.1182/blood.V126.23.5171.5171

Published: 2015

Journal Articles

Successful Management Of Calcineurin Induced Thrombotic Microangiopathy(TMA) With Eculizumab After Non- Renal Solid Organ Transplantation

Catherine Broome, MD, James K. McCloskey, MD, Raffaele Girlanda, MD

Blood (2013) 122 (21): 1078.

https://doi.org/10.1182/blood.V122.21.1078.1078

Published: 2013

NARROW

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

One Size May Not Fit All for TKI Dosing in Chronic Phase CML—Deep Molecular Responses Despite Dose Reduction

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

TP53 Mutations Determine Outcome of Patients (pts) with High-Risk Myelodysplastic Syndrome (HRMDS) and Acute Myelogenous Leukemia (AML) Regardless of Karyotype and ELN Risk Stratification

Outcome of Acute Myeloid Leukemia (AML) Induction Therapy Based on D14 Marrow Biopsy According to European Leukemia Net (ELN) Risk Classification

Evaluation of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in the Oncology Population

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Features and Outcome of Patients (Pts) with New Diagnosis of Acute Myeloid Leukemia (AML) with Monocytic Differentiation (AML-Mo) Following Standard Induction Therapy. Do We Need a Different Strategy?

A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR

A Single Institution Retrospective Review of Characteristics and Outcomes of Patients Requiring Chronic Dose Reduction of TKIs Given As Front-Line Therapy for Chronic Phase CML

Successful Management Of Calcineurin Induced Thrombotic Microangiopathy(TMA) With Eculizumab After Non- Renal Solid Organ Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only